Adicet Bio, Inc. (ACET) Stock Price, Financials & Summary

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

0.2x

Market Cap

$89.78M

MomentumView details →

1D Return

+1.70%

YTD Return

+14.00%

RSI (14)

62.3

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

0.2x

Market Cap

$89.78M

RSI (14)

62.3

MomentumView details →

1D Return

+1.70%

YTD Return

+14.00%

SummaryUpdated Jun 1, 2026

Adicet Bio, Inc. (NASDAQ:ACET) is a clinical-stage biotechnology company founded in 2014 and based in Boston, Massachusetts. The company went public in January 2018 and specializes in developing innovative cancer immunotherapies using genetically engineered immune cells. Adicet focuses specifically on gamma delta T cell therapies, representing a novel approach in the rapidly evolving field of cellular immunotherapy for treating various cancers and potentially other diseases.

Ask drillr about Adicet Bio, Inc. →

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−82.38%

ROA (TTM)

−66.80%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+45.37%

FCF YoY

+15.25%

Revenue CAGR 3Y

—

EPS CAGR 3Y

+20.35%

EBITDA YoY

+18.08%

EarningsView details →

EPS (Actual)

−$1.99

EPS Surprise

−17.75%

Beats (12Q)

4/12

Next Q EPS Est

−$1.59

Avg Surprise (4Q)

1.38%

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.11x

Current Ratio

6.71x

Quick Ratio

6.71x

Div Yield

—

Div Rate

—

Div Growth 1Y

+4.00%

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−98.97M

Op. CF (TTM)

−84.53M

Next earningsNov 4, 2026 →

Latest newsMore news →

No recent news for ACET.

Similar companies

Rallybio CorporationRLYB ImmuCell CorporationICCC Aldeyra Therapeutics, Inc.ALDX Lixte Biotechnology Holdings, Inc.LIXT Fortress Biotech, Inc.FBIO Verrica Pharmaceuticals Inc.VRCA Find similar companies →

Latest newsMore news →

No recent news for ACET.